सत्यमेव जयते
Supported by
Govt. of India

pharmexcil

Pharmaceuticals Export Promotion Council Of India

(setup by Ministry of Commerce & Industry, Govt. of India)

12th Annual Report 2015-16



INDIA
Pharmacy of the World
Responsible Healthcare

Website: www.pharmexcil.com

Contents of Annual Report 2015-16

S.No.	Subject	Pg.No.
1.	Notice for the Meeting	1
2.	Membership	5
3.	Performance of Indian Pharma Industry	7
4.	Committee of Administration	10
5.	Export Promotional Activities	14
6.	Accounts	37
7.	Circulars	60
8.	Trade Enquiries	68
9.	Benficiaries under MAI Scheme	69
10.	Benficiaries under MDA Scheme	74

Ref: PXL/H.O./CIR-054/2016-17 Date: 02.09.2016
Hyderabad

To,
All the Members of Council,

NOTICE

Dear Sir/Madam,

Notice is hereby given for 12th Annual General Meeting of the Council to be held on Friday, 23rd September 2016 (from 2:30 pm) at Hotel Park Hyatt, Banjara Hills, Hyderabad to transact the following:

AGENDA

1. To consider and approve the minutes of the 11th Annual General Meeting held on 24.09.2015 at Hyderabad.

2. Presentation of report on the activities of the Council for the year 2015-16

3. To consider and approve the report of the Auditors and the Annual General accounts of the Council for the year 2015-16

4. To appoint auditors for the year 2016-17

5. To consider any other matter with the permission of the Chair.

All members are requested to make it convenient to attend the meeting.

Thanking you,
Yours sincerely,

Dr. P V Appaji
Director General

Ref: PXL/H.O./CIR-057/2016-17 Date: 12.09.2016
Hyderabad

To,
All the Members of Council,

Dear Sir/Madam,

Sub : 12th Annual General Body Meeting on 23.9.2016 – Addition of agenda for discussion

We refer Notice dated 3rd September 2016 for 12th Annual General Body meeting to be held at 2.30 p.m. on 23rd September 2016 at Hotel Park Hyatt, Hyderabad.

We wish to inform that as advised by Committee of Administration, following additional agenda is included for discussion in the Annual General Body Meeting:

"5. To discuss and approve the proposed amendment to Articles of Association "

We enclose herewith a brief note on the proposed Amendment to Articles of Association for information of members

We also enclose herewith Annual Accounts of the Council for the year 2015-16.

With regards,

Dr. P V Appaji
Director General

Encl: Amendment
Accounts

NOTE ON PROPOSED AMENDMENT TO ARTICLES OF ASSOCIATION

As per the directions of Government vide its letter dated 7.1.2014, Council amended certain provisions of the Articles of Association, which was approved by the General Body of the Council during Emergency Meeting held on 12.2.2014.

One of the Articles amended was "4.2 – Eligibility of Ordinary Members". As per amended provision, any person standing for election as Chairman or Vice Chairman, he / she, or the entity represented him/her, must have, to his/her or its credit, during the last three financial years immediately preceding, an average export value of not less than Rs.100 crores (one hundred crores). This limit is subject to review by the Government from time to time.

Committee of Administration in its meeting held on 22.7.2016 at Mumbai discussed on this subject and decided to amend the above provision so as to reserve the Chairman / Vice Chairman post for r Small & Medium Scale manufacture Exporters with Rs.20 crores export values, for alternate terms.

Accordingly, following amendments are proposed:

1. Eligibility of Ordinary Members

Present Provision:

"4.2 (b) Where a person is standing for election as Chairman or Vice Chairman, he / she, or the entity represented him/her, must have, to his/her or its credit, during the last three financial years immediately preceding, an average export value of not less than Rs.100 crores (one hundred crores). This limit is subject to review by the Government from time to time."

Proposed Amendment:

"4.2 (b) Where a person is standing for election as Chairman or Vice Chairman, he / she, or the entity represented him/her, must have, to his/her or its credit, during the last three financial years immediately preceding, an average export value of not less than Rs.100 crores (one hundred crores) / **Rs. 20 crores (Rupees twenty crores) in case he / she, or the entity represented by him / her is a Small & Medium Scale manufacture exporter. These limits are subject to review by the Government from time to time."**

2. Vice Chairman of the Council:

Present Provision:

Vice-Chairman of the Committee

(a) There shall be one Vice-Chairman who shall be elected by the Committee for a term of two years

(b) On completion of his term of two years, Vice-Chairman shall be endorsed by the Committee to succeed the

Chairman unless:

(I) he is unwilling to accept Chairmanship or

(ii) he has incurred any of the disqualifications enumerated in Article 8.1, in regard to the membership of the Council or

(iii) he is not re-elected to Committee of Administration

Proposed Amendment:

Vice-Chairman of the Committee

(c) There shall be one Vice-Chairman, **who shall be from SME** and Non-SME sectors for alternate terms, and who shall be elected by the members of the Council for a term of two years

(d) On completion of his term of two years, Vice-Chairman shall be endorsed by the Committee to succeed the

Chairman unless:

(iv) he is unwilling to accept Chairmanship or

(v) he has incurred any of the disqualifications enumerated in Article 8.1, in regard to the membership of the Council or

(vi) he is not re-elected to Committee of Administration

MEMBERSHIP

State wise Registered Companies up to the Financial year 2015-16	
State	**No. of Regd. Companies**
Telangana	397
Andhra Pradesh	25
Assam	1
Bihar	8
Chandigarh	36
Delhi	292
Goa	14
Gujarat	496
Haryana	67
Himachal Pradesh	24
Jammu	5
Karnataka	141
Kerala	29
Madhya Pradesh	63
Maharashtra	1541
Orissa	4
Punjab	38
Rajasthan	33
Tamil Nadu	167
Uttar Pradesh	55
Uttaranchal	19
West Bengal	37
Total	**3492**

Category Wise Registered Companies	
Category	
LSM	347
SSM	1637
ME	1508
Grand Total	**3492**

Panel Wise-Registered Companies		
Panel Wise	**Description of Panel**	**No. of Members**
Panel-1	Pharmaceutical Formulations (Including zNutraceuticals, Excipients, Surgicals and Diagnostics, Veterinary Products etc)	928
Panel-2	Bulk Drugs & Drug Intermediates	674
Panel-3	Herbal Products (Including Ayurvedic, Homeopathic, Unani & Siddha Medicines)	245
Panel-4	Biotech Products	23
Panel-5	Pharmaceutical Services (Including R & D, Clinical Trials, Medical Transcripts)	65
Panel-6	Healthcare Services	74
Panel-7	Merchant Exporters (Traders, CROs)	**1483**
	Total	**3492**

INDIAN PHARMACEUTICAL INDUSTRY IN 2015-16 - AN OVERVIEW

Global Pharma market size in the calendar year 2015 is estimated at $1060 billion as per IMS with a very marginal growth rate of 1-2%. India's total exports of Pharmaceuticals (APIs, Generics and Alternative system of medicine) during 2015-16 was $16.89 billion with a growth of 9.44%. India's exports in INR terms has recorded a growth of 17% and was valued at 110,522 crore during Fy-15.

Global generic market is estimated to be of size $ 294 billion. The market grew 2015approximately by 4% as Per IMS (World renowned market audit agency) data. India, a predominant player in Global Generic market has clocked $ 12.6 billion of Exports out of this $ 294 generic market with a growth of 12.8% during the year2015-16.

Following table shows the progress of India's exports of Pharmaceuticals during the last three years.

India's Exports of Pharmaceuticals Category wise in $ mn			
Category	Fy-15	Fy-16	Gr%
Ayush	118.46	108.76	-8.19
Bulk Drugs & Drug Intermediates	3564.57	3585.05	0.57
Drug Formulations & Biologicals	11214.16	12645.51	12.76
Herbal Products	236.41	249.84	5.68
Surgicals	299.46	300.02	0.19
Grand Total	15433.06	16889.18	9.44
Source: DGCIS			

India has a market share of almost 30% of Generic market size of Africa and Middle East put together. Region of North Americahas contributed over 33% to India's pharmaceutical exports and has grown by a 26% in Fy-16 which is highest when the data is plotted by regions as shown in Table-2.

Region wise Performance in the April- March				
Row Labels	Fy-15	Fy-16	Gr%	Contb%
North America	4517.94	5704.07	26.25	33.77
Africa	3089.03	3348.55	8.40	19.83
EU	2445.49	2549.31	4.25	15.09
LAC	1076.99	1032.68	-4.11	6.11
Asean	1055.62	1031.09	-2.32	6.11
Middle East	956.12	978.51	2.34	5.79

South Asia	616.27	624.49	1.33	3.70
CIS	701.22	614.94	-12.30	3.64
Asia (Excluding Middle East)	511.68	506.37	-1.04	3.00
Oceania	263.36	294.33	11.76	1.74
Other European Countries	139.57	140.08	0.36	0.83
Other America	59.49	63.60	6.91	0.38
Others	0.27	1.16	338.30	0.01
Grand Total	15433.06	16889.18	9.44	100.00

Pictorial representation of Region wise Exports in Fy-16 $ mn



USA is the largest exporting partner of India by country and it has been so, for the last decade. During 2015-16 Exports to USA has grown over 27% and has contributed over 32% to the total. Around 55% India's exports are to highly regulated markets.

India's exports to top 25 countries during 2015-16 in $ mn							
Rank	Country	Fy-15 $ mn	Fy-16 $ mn	Growth%	Contb%	cum contbn%	Change in Value
1	U S A	4309.72	5502.96	27.69	32.58	32.58	1193.24
2	SOUTH AFRICA	511.36	606.80	18.67	3.59	36.18	95.45
3	U K	543.24	564.29	3.88	3.34	39.52	21.05
4	NIGERIA	420.50	437.26	3.98	2.59	42.11	16.76
5	RUSSIA	424.80	374.02	-11.95	2.21	44.32	-50.78
6	GERMANY	372.67	347.53	-6.75	2.06	46.38	-25.14
7	KENYA	284.20	333.21	17.24	1.97	48.35	49.00
8	BRAZIL	376.19	325.22	-13.55	1.93	50.28	-50.98
9	NETHERLAND	243.48	243.49	0.00	1.44	51.72	0.01
10	AUSTRALIA	206.20	233.25	13.12	1.38	53.10	27.05
11	FRANCE	209.00	232.16	11.08	1.37	54.47	23.17
12	VIETNAM SOC REP	233.45	221.23	-5.23	1.31	55.78	-12.22

13	SRI LANKA DSR	173.16	205.14	18.47	1.21	57.00	31.99
14	CANADA	208.22	201.11	-3.42	1.19	58.19	-7.11
15	PHILIPPINES	155.99	193.25	23.88	1.14	59.33	37.26
16	BELGIUM	154.01	192.15	24.77	1.14	60.47	38.14
17	IRAN	174.80	179.53	2.71	1.06	61.53	4.73
18	TANZANIA REP	187.44	178.51	-4.76	1.06	62.59	-8.93
19	NEPAL	169.17	170.14	0.57	1.01	63.60	0.97
20	UGANDA	158.28	169.25	6.94	1.00	64.60	10.98
21	EGYPT A RP	116.95	161.85	38.39	0.96	65.56	44.90
22	MEXICO	126.64	160.25	26.54	0.95	66.51	33.61
23	TURKEY	147.77	159.92	8.22	0.95	67.45	12.15
24	MYANMAR	172.51	154.40	-10.50	0.91	68.37	-18.11
25	THAILAND	157.37	147.71	-6.14	0.87	69.24	-9.66
	Total of the above	10237.12	11694.64	14.24	69.24	69.24	1457.52
	Grand Total	15433.06	16889.18	9.44	100		1456.12

India's Pharmaceutical industry has filed the highest number of DMFS with USFDA and by the end of year 2015, number of filings stands at 3820. India's ANDAS totaling 3470 by Feb 2016 covers all ATCs.

Following Table gives an overview of India's Accreditations.

Authority	Name of Regulatory Agency	Nos.
USA	DMFs filed with U.S. FDA (companies) (As on 31st march 2015)	238
	No: of Sites(Bulk drugs + Formulations) Registered with US FDA (as on 15th april2015)	605
	Total No Of DMF's (Type II Active) Filed from India (as on 31 St Dec 2015)	3820
	ANDAs(As on Feb 2016)	3470
EUROPE	Formulation companies with USFDA approvals.	53
	Number of CEPs received (as of February 2016)	1354
	Number of companies with CEPs	220
	Number of Molecules for which CEPs have been filed with EDQM	382
	No of Sites with EU GMP Compliance as on 15thFebruary 2016	631
	UK MHRA (Medicines Healthcare Regulatory Agency), Market authorizations as on March 2015	1559
	Number of CEPs with Irish Medicines Board	300
	Number of companies registered in Irish Medicines Board	19
	Number of Authorisations with Sweden MPA (Läkemedelsverket)	209
	Number of companies having MA`s with Sweden MPA (Läkemedelsverket)	14
WHO GMP	WHO GMP Certified Plants (as per Drug Controller General of India)	1400 (approx.)
Ethiopia	DACA (Drug Administration and Control Authority), Ethiopia (companies)	50
Tanzania	(TFDA) Tanzania Food and Drugs Authority (companies)	1373

Committee of Administration
w.e.f 05-07-2016 (for 2 years)

Chairman
Sri Madan Mohan Reddy
Director
Aurobindo Pharma Limited

Vice Chairman
Sri Dinesh Dua
CEO& Director
Nectar Life Sciences Limited

Government Nominees	
Sri Sudhanshu Pandey, IAS Jt. Secretary Department of Commerce Ministry of Commerce & Industry Government of India	**Shri Sudhansh Pant** Jt. Secretary Department of Pharmaceuticals Ministry of Chemicals & Fertilizers Government of India
Sri. K L Sharma Jt. Secretary Department of Health Ministry of Health & Family Welfare Government of India	**Dr. T S Rao** Senior Advisor Department of Biotechnology Ministry of Science & Technology Government of India

Elected Members	
Shri Devang B Shah Director Aadivighnesh Chem Pvt Ltd Mumbai	**Shri Bharat Desai** Managing Director Bharat Parenterals Limited Vadodara
Shri Tushar A Korday Director Emil Pharmaceutical Industries Pvt Ltd Mumbai	**Dr. A.R. Venkatesh** Chief Executive Officer Global Pharma Healthcare Private Limited Chennai
Shri Sandeep V Bambolkar Jt. Managing Director Indoco Remedies Ltd Mumbai	**Shri Sahil Munjal** President & Chief Executive Officer Ind-Swift Laboratories Ltd Chandigarh

Elected Members

Shri Bhavin Patel Partner Mediwin Pharmaceuticals Ahmedabad	**Shri Atul Bhopale** Executive Director Nexgen Healthcare Pvt Ltd Mumbai
Shri Dodda VVS Reddy Director Nosch Labs Limited Hyderabad	**Dr. Janmejay H Patel** Chief Executive Officer Petlad Mahal Arogya Mandal Pharmacy Nadiad
Shri Fazal Abbas Virji Director Shalina Laboratories Pvt Ltd Mumbai	**Shri P Ramesh Babu** Chairman & Managing Director SMS Pharmaceuticals Limited Hyderabad
Shri Vijay Shah Managing Director Stallion Laboratories Pvt ltd Ahmedabad	**Shri Siddharth Daga** Executive Director VinsBioproducts Ltd Hyderabad

Ex-Officio Members from National Associations

Shri S V Veerramani President Indian Drug Manufacturer's Association (IDMA) Mumbai	**Shri M Jayant Tagore** President Bulk Drug Manufacturer's Association (BDMA) Hyderabad
Shri Nilesh Gupta President Indian Pharmaceuticals Alliance (IPA) Mumbai	**Dr. P M Varier** President Ayurvedic Drug Manufacturer's Association (ADMA)
Dr. P M Murali President Association of Biotechnology Led Enterprises (ABLE)	
SECRETARIAT **Dr. P.V. Appaji** Director General & Member Secretary	

Committee of Administration 2015-16

Chairman

Sri Ashutosh Gupta
Executive Director
Medicamen Biotech Limited

Vice Chairman

Sri Madan Mohan Reddy
Director
Aurobindo Pharma Limited

Government Nominees

Sri Sudhanshu Pandey, IAS Jt. Secretary Department of Commerce Ministry of Commerce & Industry Government of India	**Shri Sudhansh Pant,** IAS Jt. Secretary Department of Pharmaceuticals Ministry of Chemicals & Fertilizers Government of India
Sri. K L Sharma Jt. Secretary Department of Health Ministry of Health & Family Welfare Government of India	**Dr. T S Rao** Senior Advisor Department of Biotechnology Ministry of Science & Technology Government of India

Elected Members

Shri Paresh Chawla Director Alpa Laboratories Limited Indore	**Shri Manish Jajodia** Proprietor Anzen Exports Kolkata
Shri Dipak Desai Director Aurochem Laboratories (India) Private Limited Mumbai	**Shri Bharat Desai** Managing Director Bharat Parenterals Limited Vadodara
Dr. A.R. Venkatesh Chief Executive Officer Global Pharma Healthcare Private Limited Chennai	**Dr. Pardhasaradhi Reddy** Chairman & Managing Director Hetero Drugs Limited Hyderabad

Elected Members

Shri Bhavin Mehta Kilitch Drugs (India) Limited Director Mumbai	**Dr. C Satyanarayana** Chief Executive Officer Laurus Labs Private Limited Hyderabad
Shri SM Mudda Executive Director Micro Labs Limited Bangalore	**Shri C Bharat Reddy** Director MSN Laboratories Limited Hyderabad
Shri Rajeev Nannapaneni Chairman & Managing Director Natco Pharma Limited Hyderabad	**Dr. Janmejay H Patel** Chief Executive Officer Petlad Mahal Arogya Mandal Pharmacy Nadiad
Shri Nipun Jain Director Pharmchem Delhi	**Sri Venkat Jasti** Chairman &Chief Executive Officer Suven Life Sciences Limited Hyderabad

Ex-Officio Members/National Associations

Shri S V Veeramani President Indian Drug Manufacturer's Association (IDMA) Mumbai	**Shri M Jayant Tagore** President Bulk Drug Manufacturer's Association (BDMA) Hyderabad
Shri K Satish Reddy President Indian Pharmaceuticals Alliance (IPA) Mumbai	**Dr. P M Varier** President Ayurvedic Drug Manufacturer's Association (ADMA)
Dr. P M Murali President Association of Biotechnology Led Enterprises (ABLE)	
SECRETARIAT **Dr. P.V. Appaji** Director General & Member Secretary	

Export Promotional Activities

INTERNATIONAL EVENTS

a) Phrarmaconex, Egypt

Council participated in Pharmaconex, Egypt, for the 3rd time, which held during 18 - 20th April 2015 at Cairo, Egypt. 23 Indian companies participated in the event. During the event, Council officials met the senior officials of Ministry of Health, Commerce, Drug Regulatory / biotechnology officials and discussed with them about issues of fast registration of products by Indian companies etc. Council also organized exclusive networking dinner, where about 130 local buyers / traders participated and interacted with the exhibitors.

b) CPhI China

India Pavilion was organized in CPhI China during 24 - 26th June 2015. 23 Indian companies participated in the show. This event is becoming more popular and more number of Indian companies are showing interest to participate and promote their exports in China.



c) CPhI Istanbul

For the Second time, Council participated in CPhI Istanbul held in 3rd - 5th June 2015, by organizing India Pavilion. 26 Indian companies participated through pavilion. Council planned for increased space for next year's participation.

d) Korea Pharm: 21-24 April 2015

For the 3rd time, Council participated in Korea Pharm held in June 2014. 12 Indian companies participated in the India pavilion.

e) BSM cum Expo at Latin America

Buyer Seller Meet and Expo was organized during 23rd August -5th Sep.2015 at Peru, Paraguay, Chile, and Argentina, where about 42 Indian companies participated. Council organized B2B meetings by inviting local pharma companies / traders / associations and also met the officials of Drug Regulatory agencies at all places.

f) BSM cum Expo at Russia followed by Business Delegation to Belarus & Uzbekistan during 24th Feb-5th March 2016

Buyer Seller Meet and Expo was organized during 24th Feb to 27th Feb at Russia followed by Delegation to Belarus and Uzbekistan during 27th Feb to 5th March 2015, where about 75 Indian companies and 125 foreign buyers participated. Council organized B2B meetings by inviting local pharma companies / traders / associations and also met the officials of Drug Regulatory agencies at all places.

g) CPhI Worldwide during 13-15 October 2015

Council organized India Pavilion in CPhI WW for the 10thtime. A high level delegation led by Ms.Rita Teaotia, Secretary, Shri Sudhanshu Pandey, Joint Secretary, Shri B P Pandey, Additional Secretary, Shri G N Singh, DCGI attended and interacted with the participants. As part of Brand India Pharma programme, several meetings with stake holders, press conferences etc. were organized with the help of IBEF.

h) Arab Health during 25 - 28th January 2016

Council participated in this event held during 25 - 28th January 2016, for the 9th consecutive year and organized India Pavilion. 51 companies participated in the Pavilion. A Business Center was also organized, where about 50 Indian exporters had meetings with overseas delegates. Considering ever increasing potential for this event, it is proposed to organize Expo - BSM also next year.

I) Business delegation to ASEAN countries:

A business delegation to Cambodia, Vietnam and Thailand was organized by Council during 13 - 23rdMarch 2016. The delegation was led by Mr.Udaya Bhaskar, Additional Executive Director and coordinated by Mr.Murali Krishna.Council with the association of Embassies, Indian Chambers of Commerce in Cambodia,Vietnam Chamber of Commerce and India Thai Chambers of Commerce organized Seminars and B2B meetings at all the three locations. B2B meeting were well attended by local companies / distributors. 35 Indian companies participated in the business delegation.

j) IPHEX Africa during 18-19th February,2016 :

The first edition of IPHEX Africa was organized by the Council during 18th Feb to 19th Feb 2016 at Nigeria, Lagos, where about 84 Indian companies and 800 foreign buyers participated. Council organized Expo and B2B meetings by inviting local pharma companies / traders / associations and also met the officials of Drug Regulatory agencies at all places.

India Pavilion at Vitafoods during 5-7th May 2015:

Vitafoods is widely regarded as the flagship exhibition for Herbal products, nutraceuticals, probiotics, pharmaceutical ingredients industry, dietary supplements etc. Council is participating in this event for the last six years and this is seventh year of successful participation at Vita foods. Council has taken a space of 81 sqmts and organized India Pavilion with 10 companies including Pharmexcil.

India Pavilion at Supply Side West during 7-8th October 2015:

Supply Side West is widely regarded as the flagship exhibition for Herbal products, nutraceuticals, probiotics, pharmaceutical ingredients industry, dietary supplements etc. Council is participating in this event for the last five years and this is sixth year of successful participation at SSW. Council has taken a space of 92 sqmts and organized India Pavilion with 10 companies including Pharmexcil.

NATIONAL EVENTS

a) IPHEX 2015

3rdedition of IPHEX was successfully held during 13 - 15th May 2015. Council made elaborative efforts to invite prominent buyers from various countries. The event was inaugurated by Shri Hansraj Gangaram Ahir, Minister of State for Chemical & Fertilisers as the Chief Guest. Over 550 importers / buyers / manufacturers have been sponsored to participate in the B2B meetings organized over 3 days. Response from Indian companies to participate in the exhibition was also encouraging as over 401 companies participated as exhibitors.

b) Seminars organized during IPHEX 2015

The following technical seminars were organized during the IPHEX 2015.

- Regulatory Perspective for Global Opportunities in Nutraceuticals
- Indian Pharmacopeia-A Book of Global Standards

- Regulatory Actions by USFDA-Strategies to handle Business Risks
- Interactive Meeting with Overseas Regulators

Shri Sudhanshu Pandey, Joint Secretary attended the meeting and interacted with the participants. The meeting was well attended by the members.

i) CPhI India

India - Pharmexcil pavilion was organized by Council at CPhI India held during 1st - 3rd December 2015 at Mumbai. This is the 9th consecutive year Council with the Ministry of Commerce & Industry, organizedIndia Pavilion. 90 Indian companies participated in the pavilion. All the exhibitors got good response. Over 5000 visitors visited the pavilion and interacted with the participants.

Global Pharma Business Meet:

Council organized an event "Global Pharma Business Meet, focusing mainly on promotion of API sector, coinciding Council's 11th Annual Meet during 22-24th September 2016.

85 overseas delegates from 31 countries have been invited. Out of 85 delegates, 52 are manufacturers of pharmaceutical formulations looking for APIs, packing material, pharma machinery etc, thus giving more focus for promotion of API sector. About 200 Indian companies participated in the B2B meetings arranged for 3 days.

Exhibition: 12 Indian pharma companies exhibited in the show.

Technical & Commercial Seminars:

On the sidelines of Global pharma Business Meet, Council organized seminars on technical and commercial subjects for the benefits of Indian pharma industry:

1. Data Integrity: Eminent persons from industry like Mr. S M Mudda, Executive Director of Micro Labs, Bangalore etc. have made presentations on the subject. The event was coordinated by EY
2. Financing in Pharm Sector: Senior officials of Exim Bank and SBI Factoring have made presentations on financing solutions available to Pharma industry.
3. Packaging Innovations: Mr. Chakravarthy, Managing Director of Ecoblis, Hyderabad made presentation on innovating technologies in Packaging.
4. WHO Prequalification Programme - APIs, Finished formulations, Quality Control Laboratories - b Dr Milan Smid, Dr Antony Fake, Mr Rutendo Kuwana: all WHO Prequalification Team technical officers made presentation on how to get prepared for inspection by WHO
5. Clinical Research eminent person from the industry & academia made presentations
6. PICS Implications : Senior officials from IMS Healthcare made presentations about India's prepared to join PICs

Pharma CEOs Conclave:

"Present Challenges & Preparedness of Indian Pharma Industry" was the theme for Pharma CEOs Conclave held on 23rd September 2016. Shri Satish Reddy, Dr. Reddy's Laboratories Limited was the Chairman of Panel discussion. Shri Rajiv Nannapaneni, CMD of Natco Pharma, Dr. Shiv Kumaran, Director, Aurobindo Pharma Ltd, Dy. MD of Exim Bank, Directors of Drug Control Administration of Telangana and AP State Governments participated in the Pharma CEOs Conclave

Export & Patent Awards:

Council distributed awards to the selected companies for their outstanding performance in exports and also obtaining Patents

Buyer-seller meet at Pharmac South expo focused to ASEAN Region during 3-4th July 2016 at Chennai

The international buyer-seller meet (BSM) organised by the Pharmaceuticals Export Promotion Council of India (Pharmexcil) last week in Chennai as part of the pharma trade exhibition (Pharmac South) has evoked good response and helped the pharmaceutical manufacturers in south India establish a direct link with buyers from ASEAN and Gulf countries.

The two-day meet, inaugurated by Suthamshu Pandey, joint secretary, ministry of commerce, on July 3 at Chennai Trade Centre, was organised by the Tamil Nadu branch of the Indian Drugs Manufacturers' Association (IDMA) in association with Pharmexcil. The BSM has encouraged the small scale pharmaceutical companies in the southern states, especially from Tamil Nadu and Puducherry, to become potential exporters to the ASEAN nations from where buyers have come to Chennai to interact with the local manufacturers. The foreign buyers attended the meet could achieve more business contracts than what they had expected. The buyer-seller meet and trade exhibition was visited by the health ministry officials from Timor Leste, a member of ASEAN, under the leadership of the country's vice-minister of health, Dr. Ana Isabel de Fatima Sousa Soares. The minister's accompanying official group included the country's head of pharmacy, Jonia Lourenca Nunes Brites da Cruz.

Ten potential buyers from Cambodia, Laos, Timor Leste, Malaysia and from UAE were present at the meeting.

Buyer Seller Meet at India Pharma Expo during 7-9th Jan.2016

The Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers in association with the Pharmexcil organized Buyer Seller Meet during INDIA PHARMA-2016 at Bangalore International Exhibition Centre, Bengaluru, Karnataka from January 7-9, 2016.

Twenty overseas delegates from eleven countries and about 100 Indian companies participated in the Buyer Seller Meet.

Buyer Seller Meet at Arogya Expo during 12-13thDec.2016

Pharmexcil organized Buyer Seller Meet during Arogya Expo at Benarus Hindu University scheduled during 12-13 Dec.2016.Arogya Expo is organized by Ministry of AYUSH for three days from 11-13

Twelve overseas delegates from five countries and about 50 Indian companies participated in the Buyer Seller Meet.

c) Buyer Seller Meet at Bio Asia 2016 during 8-10,Feb.2016

Council organized International Pharma Business meet coinciding Bio Asia during 8-10th February 2016 by inviting 24 overseas delegates from various countries. About 70 Indian exporters participated in the Business meetings.

OTHER IMPORTANT SEMINARS & WORKSHOPS

15 April 2015: Presentations / Panel Discussions on Foreign Trade Policy 2015-20 Meeting with Jt.DGFT, Hyderabad

01 May 2015: Interactive Dinner with EU Delegates, New Delhi

07 May 2015: Interactive Meeting on Foreign Trade Policy 2015-20, Mumbai

26 May 2015: Meeting with "Members of Parliamentary Standing Committee on Commerce", Hyderabad

27 May 2015: Interactive Meeting with Overseas Regulators in CDSCO, Hyderabad - Jointly Organised by Pharmexcil & USP

26 June 2015: Seminar on Bar Coding / Drug Authentication and Verification Application, Mumbai

29 June 2015: Launch of Central Server for Track and Trace Implementation and DGFT Announcements by Shri Rajeev Kher, Secretary, DoC in New Delhi

05 August 2015: Inauguration of Pharmexcil's Branch Office at Bangalore & Technical Seminar on "Export Opportunities and Regulatory Challenges for Pharmaceuticals & Traditional Medicines"

06 August 2015: Joint Workshop by Pharmexcil & IDMA on "Pharma Product positioning and export benefits under various Government Schemes", Chennai

18 Aug 2015: Make in India - Make in AP; Program organized by Drugs Control Organization, Govt of AP under chairmanship of Hon'ble Health Minister, Mr Kamineni Srinivas, Vizag

24 August 2015: Seminar on Bar Coding, Hyderabad

07 October 2015, Seminar on "Export of AYUSH & Nutraceutical Products and its Procedures", Ahmedabad

20 December 2015, Regulators meet at Indian Pharmaceutical Congress (IPC), Mysuru

05 February 2016, Seminar on Outreach programme for utilization of Free Trade Agreements (FTAs) & other Pharma related issues, Ahmedabad

08-10 February 2016, BioAsia 2016 - Seminars & One to One Meetings with Regulators / Govt. Procurement Agencies, Hyderabad

12 February 2016, Interactive Meeting with the Director, US FDA, India office at Hyderabad

17 February 2016, Seminar under "Niryat Bandhu" for Pharma Cluster at Mumbai

25 February 2016, Interactive Meeting of UK MHRA Officials & Indian Regulators at CDSCO, Hyderabad

26 February 2016, Interactive Seminar with UKMHRA Officials at Taj Deccan, Hyderabad

01 March 2016, Post Budget 2016-17 (Analysis - Pharma Focus) by Pricewaterhouse Coopers (PwC) at Taj Deccan, Hyderabad

03-04 March 2016, Two Days Certification Course on Export Import Management, Mumbai

Accounts for 2015 - 16

INDEPENDENT AUDITOR'S REPORT ON FINANCIAL STATEMENTS

To
The Members of
M/s PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
Hyderabad.

Report on the Financial Statements

We have audited the accompanying financial statements of **M/SPHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA("M/s Pharmexcil")**, which comprise the Balance Sheet as at 31st March 2016, the Statement of Income and Expenditure Account and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements and for Internal Financial Controls over Financial Reporting

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business,

including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit and to express an opinion on the Company's internal financial controls over financial reporting based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement and whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

An audit involves performing procedures to obtain audit evidence about the amounts, the disclosures in the financial statements and adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exits, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting and the financial statements.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial controls over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2016, and its Surplus for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

(c) The Balance Sheet, the Statement of Income and Expenditure dealt with by this Report are in agreement with the books of accounts.

(d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(e) On the basis of the written representations received from the directors as on 31st March, 2016 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2016 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) In our opinion considering nature of business, size of operation and organizational structure of the entity, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2016, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

(g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

   i. The Company does not have any pending litigations which would impact its financial position.

   ii. The Company did not have any long-term contracts includingderivative contracts for which there were any material foreseeable losses.

iii. There has been no requirement of amounts to be transferred to the Investor Education and Protection Fund by the Company.

(h) The provisions of Companies (Auditors Report) Order, 2016 do not apply to the Company as it is licensed to be operated under Section 8 of the Companies Act and is hence exempted to be reported in accordance with clause 2(iii) of the said Order.

for SARATH & ASSOCIATES
Chartered Accountants
FirmRegn No. 005120S

CA S Srinivas
Partner
M. No.202471

Date : 22-07-2016
Place: Hyderabad

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
(LIMITED BY GUARANTEE)
BALANCE SHEET AS AT 31st March, 2016

(Amount in Rs.)

CORPUS FUND & LIABILITIES	SCH.	As on 31.03.2016	As on 31.3.2015
Corpus Fund		3,00,00,000	3,00,00,000
Reserves & Surplus	1	1,05,14,125	84,41,125
Capital Grants	2	0	0
Advances from Govt.of India	3	4,87,94,215	3,74,30,769
Current Liabilities & Provisions	4	14,17,30,467	11,72,17,806
Excess of Income over Expenditure	4 (A)	8,66,86,453	4,55,12,706
		31,77,25,260	**23,86,02,406**
ASSETS	**SCH.**	**As on 31.03.2016**	**As on 31.3.2015**
Fixed Assets	5	51,00,002	55,90,203
Investments	6	7,00,00,000	3,87,22,123
Current Assets, Loans & Advances	7	24,26,25,258	19,42,90,080
		31,77,25,260	**23,86,02,406**

Vide our Report of Even Date
For SARATH & ASSOCIATES
FRN: 005120S
Chartered Accountants

For Pharmaceuticals Export Promotion Council of India

CA S.SRINIVAS
Partner
M.No. 202471

Director General

Chairman

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
(LIMITED BY GUARANTEE)
INCOME & EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

INCOME	SCH.	As at 31.03.2016	As at 31.03.2015
Membership Fees	8	4,00,18,499	3,88,88,264
Contributions from Members	9	19,46,96,078	18,28,06,123
Income from Investments	10	51,98,784	32,64,370
Other Income	11	76,38,927	14,90,879
		24,75,52,288	**22,64,49,636**
EXPENDITURE	**SCH.**	**As at 31.03.2016**	**As at 31.03.2015**
Expenses on Coded Activities	12	16,12,09,959	16,83,47,832
Establishment Expenses	13	2,35,60,930	2,26,74,715
Other Administrative Expenses	14	2,06,76,730	1,76,57,058
Depreciation on Assets	5	9,30,922	9,90,998
		20,63,78,541	**20,96,70,603**
Surplus for the year carried to Schedule 1A		**4,11,73,747**	**1,67,79,033**

Vide our Report of Even Date
For SARATH & ASSOCIATES
FRN: 005120S
Chartered Accountants

For Pharmaceuticals Export Promotion Council of India

CA S.SRINIVAS
Partner
M.No. 202471

Director General

Chairman

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

PARTICULARS		As at 31.03.2016		As at 31.03.2015
SCHEDULE - 1				
RESERVES & SURPLUS				
ENTRANCE FEE				
As per last Account	84,41,125		65,27,625	
Add: Entrance Fee collected from New Members	20,73,000	1,05,14,125	19,13,500	84,41,125
		1,05,14,125		**84,41,125**
SCHEDULE - 2		**As at**		**As at**
CAPITAL GRANTS		**31.03.2016**		**31.03.2016**
As per last Balance Sheet	0		1,03,178	
Add: Received during the year	0		0	
	0		1,03,178	
Less: Adjustments during the year (60% of depn on assets for which Grant recd. from Govt)	0	0	1,03,178	0
		0		**0**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

SCHEDULE - 3 (A) ADVANCE FROM GOVT.OF INDIA		As at 31.03.2016		As at 31.03.201
(I) Advances under MDA Scheme Refundable to the extent remaining unutilised				
As per last Balance Sheet	0		13,00,507	
Add: Received during the year	6,00,00,000		3,65,00,000	
	6,00,00,000		3,78,00,507	
Less: UTILISED BY THE COUNCIL				
(I) For Specific Code Activities	4,15,00,000		3,65,00,000	
(ii) Amount returned to Ministry	0		13,00,507	
	4,15,00,000	1,85,00,000	3,78,00,507	0
(II) Advances under Exporters MDA Claims Refundable to the extent remaining unutilised				
As per Last Balance Sheet	25,76,583		69,43,583	
Add: Received during the year	3,00,00,000		2,60,00,000	
	3,25,76,583		3,29,43,583	
Less: Amount returned to Ministry	40,61,257		36,54,000	
Less: MDA disbursed during the year	2,10,63,260		2,67,13,000	
	2,51,24,517	74,52,066	3,03,67,000	25,76,583
(III) Advances under MAI Scheme Refundable to the extent remaining unutilised				
As per Last Balance Sheet	3,37,46,577		2,43,65,124	
Add: Received during the year				
- Reimbursement of Product Regn. charges	14,89,35,952		2,33,25,566	
- Grants received for activities under MAI	6,19,38,969		10,16,00,000	
- Grants receivable for activities under MAI	4,42,84,783		3,38,31,335	
	28,89,06,281		18,31,22,025	
Less: Disbursed during the year				
- Returned to Ministry	1,05,14,730			
- Product Registration Charges	14,87,59,331		2,50,25,162	
- Utilised for Activities under MAI Scheme	10,67,90,071		12,43,50,286	
	26,60,64,132	2,28,42,149	14,93,75,448	3,37,46,577
(IV) Advances from Ministry of Chem & Fertilizers Refundable to the extent remaining unutilised				
GRANTS RECEIVED FOR IPR CELL				
As per last Balance Sheet	11,07,609		0	
Add: Received during the year	0		33,75,000	
Less: Utilised during the year	11,07,609	0	22,67,391	11,07,609
		4,87,94,215		**3,74,30,769**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

SCHEDULE - 4 CURRENT LIABILITIES & PROVISIONS		As at 31.03.2016		As at 31.03.2015
Sundry Creditors for Expenses	2,71,42,683		2,61,95,461	
Outstanding Expenses	2,96,63,330		3,23,46,126	
TDS Payable	9,94,677		7,47,459	
Advance Contributions from Members	8,31,39,000		5,72,59,983	
Vat Refund Cphi-Paris (12-13)	5,88,377		5,88,377	
Visa Fee for Delegations	2,02,400	14,17,30,467	80,400	11,72,17,806
		14,17,30,467		**11,72,17,806**
SCHEDULE - 4(A) EXCESS OF INCOME OVER EXPENDITURE		**As at 31.03.2016**		**As at 31.03.2015**
Opening Balance	4,55,12,706		2,87,33,673	
Add: Surplus as per Income & Exp. Account	4,11,73,747	8,66,86,453	1,67,79,033	4,55,12,706
		8,66,86,453		**4,55,12,706**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

SCHEDULE - 5 FIXED ASSETS								
	GROSS BLOCK			DEPRECIATION			NET BLOCK	
PARTICULARS	As on 01-04.2015	Additions during the Year	As on 31.03.2016	Upto 31.03.2015	Provided during the Year	Upto 31.03.2016	As on 31.03.2016	As on 31.03.2015
Lease hold land	5,58,302	0	5,58,302	0	0	0	5,58,302	5,58,302
Vehicles	48,43,098	0	48,43,098	9,62,558	4,59,421	14,21,979	34,21,119	38,80,540
Computers	33,43,864	4,11,054	37,54,918	32,14,247	1,10,975	33,25,222	4,29,696	1,29,617
Office Equipments	17,29,883	16,500	17,46,383	7,73,921	3,46,607	11,20,528	6,25,855	9,55,962
Intangible Assets - Software	2,87,111	0	2,87,111	2,87,111		2,87,111	0	0
Furniture & Fixtures	1,90,362	13,167	2,03,529	1,24,580	13,919	1,38,499	65,030	65,782
Computers - IPR CELL	9,91,312	0	9,91,312	9,91,312		9,91,312	0	0
TOTAL	**1,19,43,932**	**4,40,721**	**1,23,84,653**	**63,53,729**	**9,30,922**	**72,84,651**	**51,00,002**	**55,90,203**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

SCHEDULE - 6 INVESTMENTS		As at 31.03.2016		As at 31.03.2015
Fixed Deposits with Corporation Bank, Hyderabad	3,00,00,000		3,00,00,000	
Fixed Deposits with Corporation Bank, Hyderabad	4,00,00,000	7,00,00,000	87,22,123	3,87,22,123
		7,00,00,000		**3,87,22,123**
SCHEDULE - 7 **CURRENT ASSETS, LOANS & ADVANCES**		**As at** **31.03.2016**		**As at** **31.03.2015**
CURRENT ASSETS				
Cash in hand	1,33,062		1,56,282	
Bank Balance	12,52,22,696		10,54,03,717	
		12,53,55,758		**10,55,59,999**
LOANS & ADVANCES				
Rent Deposit	10,98,022		10,98,022	
Other Deposits	37,915		37,915	
Interest accrued on deposits	50,84,128		27,15,316	
TDS Receivable	2,52,57,016		1,64,38,564	
Advance for expenses-Delhi	5,00,000		6,91,387	
Amount receivable for activities under MAI Scheme	4,78,88,839		3,66,31,641	
Sundry Debtors	2,57,28,632		2,13,49,579	
Advance to staff	4,76,149		2,76,019	
Brand Promotion Funds Receivable from IBEF, Delhi	52,06,839		52,06,839	
Advances paid for next year activities	31,84,463		35,20,358	
Service Tax	11,83,197		2,17,587	
Tour Advances to Staff	16,24,300		5,46,854	
		11,72,69,500		**8,87,30,081**
		24,26,25,258		**19,42,90,080**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

SCHEDULE - 8 MEMBERSHIP FEE		As at 31.03.2016		As at 31.03.2015
Membership Fee	4,00,18,499	4,00,18,499		3,88,88,264
		4,00,18,499		**3,88,88,264**
SCHEDULE - 9 **CONTRIBUTION FROM MEMBERS**		**As at** **31.03.2016**		**As at** **31.03.2015**
Income from Exhibitions/Trade Fairs	10,13,13,937		9,80,03,673	
Income from Delegations	91,54,897		47,20,000	
Income from Reverse Delegations	8,29,72,928		7,90,36,747	
Income from Advertisements in Event Catalogues	12,54,316	19,46,96,078	10,45,703	18,28,06,123
		19,46,96,078		**18,28,06,123**
SCHEDULE - 10 **INCOME FROM INVESTMENTS**		**As at** **31.03.2016**		**As at** **31.03.2015**
Interest on Fixed Deposits				
- on Corpus Fund of Rs.300 Lakhs	24,00,000		29,86,256	
- on fixed deposits with scheduled banks	27,98,784	51,98,784	2,78,114	32,64,370
		51,98,784		**32,64,370**
SCHEDULE - 11 **OTHER INCOME**		**As at** **31.03.2016**		**As at** **31.03.2015**
Sale of Publications	49,948		59,650	
Certification Charges	1,25,345		1,63,750	
Other Income (including MAI processing charges)	74,63,634		12,67,479	14,90,879
		76,38,927		**14,90,879**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

SCHEDULE - 12 EXPENSES ON CODED ACTIVITIES		As at 31.03.2016		As at 31.03.2015
Activities under MDA Scheme				
Exhibitions/Trade Fairs outside India	5,13,69,531			6,88,83,326
Delegations outside India	1,90,42,191			1,57,35,781
Export Promotion Seminars & Meetings	37,13,434			15,90,981
Reverse Delegations	2,70,45,653			1,75,80,570
Publicity & Canvassing - Abroad	18,96,541			8,79,958
	10,30,67,350			**10,46,70,616**
Activities under MAI Scheme				
Iphex - Mumbai	8,02,87,559			8,75,15,163
Arab Health Exhibition Dubai	2,31,08,078			1,97,36,071
Expo-cum-BSM Peru	73,66,625			-
Gobal Pharma Meet, Hyderabad	1,24,41,900			71,39,120
Iphex - Nigeria	1,66,89,785			78,69,309
India Pharma Expo - Bangalore	23,58,679			72,56,547
RBSM in 6th World Ayurveda Congress	-			76,44,014
Expo-cum-BSM Myanmmar	-			66,55,498
Expo-cum BSM in Vietnam	-			61,42,890
BSM CUM EXPO in Moscow	1,17,13,155			1,07,31,775
Cphi - World Wide Exhibition in Spain	5,10,49,874			6,38,06,342
	20,50,15,655			**22,44,96,729**
Activities without Grant	**14,17,025**			**46,38,793**
(A) : Expenses on Coded Activities	**30,95,00,030**			**33,38,06,138**
Less: MDA Grants received from Govt.of India	4,15,00,000			3,65,00,000
MAI Grants received from Govt.of India	10,67,90,071			12,89,58,306
(B) : Total Grants	**14,82,90,071**			**16,54,58,306**
(A) - (B)	16,12,09,959			16,83,47,832
		16,12,09,959		**16,83,47,832**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2016

(Amount in Rs.)

PARTICULARS		As at 31.03.2016		As at 31.03.2015
SCHEDULE - 13				
ESTABLISHMENT EXPENSES				
Salaries	1,88,47,345		1,72,72,453	
Exgratia to Employees	12,52,891		9,51,153	
Medical Benefits to staff	2,91,111		3,10,201	
Staff Welfare Expenses	2,08,067		3,60,982	
L.T.A	9,00,893		0	
E.P.F Employer's Contribution	17,43,623		11,36,059	
Gratuity	3,17,000		26,43,867	
		2,35,60,930		**2,26,74,715**
SCHEDULE - 14		**As at**		**As at**
OTHER ADMINISTRATIVE EXPENSES		**31.03.2016**		**31.03.2015**
Audit Fee	4,41,400		2,00,000	
Advertisement Expenses	2,23,920		1,15,000	
Bank Charges	1,42,834		1,06,108	
Books & Periodicals	98,237		99,165	
Building Maintenance	3,25,933		2,14,326	
COA Meeting Expenses	70,336		4,97,699	
Consultancy Charges	31,23,236		9,58,984	
Conveyance	15,18,673		17,96,371	
Electricity Charges	12,42,525		10,60,724	
Internet/Website	10,32,519		3,58,998	
Office Expenses	17,14,685		30,57,045	
Postage & Courier	9,22,163		10,43,089	
Printing & Stationery	13,81,919		5,91,666	
Rent	40,36,958		30,85,340	
Telephone	7,39,548		8,14,444	
Travelling Expenses	27,32,043		17,04,623	
Subscriptions	36,129		11,461	
Exchange Rate Flucutuation	0		-41,656	
Vehicle Maintenance	4,36,723		4,02,225	
Repairs & Maintenance	3,67,049		15,22,438	
Insurance	61,911		59,008	
Swach Bharath Cess	27,989		0	
		2,06,76,730		**1,76,57,058**
		4,42,37,660		**4,03,31,773**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA

(LIMITED BY GUARANTEE)

01 Company overview

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA ("**M/s Pharmexcil**"), a non profit company (hereinafter called the 'Council'), within the meaning of Section 8 of the Companies Act, 2013 (earlier Section 25 of the companies Act, 1956), was incorporated in India on the 1st day of April 2004 and by the virtue of Provisions of the Companies Act, the word "LIMITED" is not required to be suffixed in its name.

M/s Pharmexcil has been set up by the Ministry of Commerce and Industry to act as a Nodal Agency for issue of registration cum Membership certificates. Pharmaceutical exports through out the country under the provisions of foreign trade policy being announced by the Government of India from time to time.

02 Significant accounting policies

2.1 Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year unless stated otherwise.

2.2 Use of estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) as on the date of financial statements and reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialised.

2.3 Investments

Long-term investments are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Interest on the same is being accounted for on accrual basis.

2.4 Tangible fixed assets

Fixed assets are stated at cost of acquisition including any cost attributable for bringing the assets to its working condition less accumulated depreciation .The cost of assets less accumulated depreciation up to the date of disposal are recognised in the Statement of Income and Expenditure.

2.5 Depreciation on Tangible fixed assets

Fixed Assets are stated at cost less accumulated depreciation. Cost includes all expenses related to acquisition and installation of the concerned assets and any attributable cost of bringing the asset to the condition of its intended use.

Depreciation on tangible assets is provided on the Straight line method by considering useful lives of assets specified in Schedule-II of the Companies Act 2013. Depreciation for assets purchased / sold during a period is proportionately charged.

2.6 Cash and cash equivalents

Cash and cash equivalents comprises cash on hand and cash in bank

2.7 Employee benefits:

Defined contribution plans

The Company's contribution to provident fund, superannuation fund and National Pension Scheme are considered as defined contributionplans and are charged to the Statement of Income and Expenditure as they fall due, based on the amount of contribution required to be made and when services are rendered by the employees.

2.8 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured and Entry fee collected is credited to General Reserve directly.

2.9 Operating leases

Leases under which all the risks and benefits of ownership are effectively retained by the lessor are classified as operating leases. Amount due under the operating leases are charged to the Statement of Income and Expenditure, on a straight-line method, over the lease term in accordance with Accounting Standard 19 on 'Leases'. Initial direct costs incurred specifically for operating leases are recognised as expense in the year in which they are incurred.

2.10 Foreign currency transactions and translations

Transactions in foreign currencies of the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction. Foreign currency monetary items outstanding at the Balance Sheet date are reported using the closing rate. Gain or loss resulting from the settlement of such transactions and translations of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Income and Expenditure.

2.11 Provisions and contingencies

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

2.12 Service tax input credit

Service tax input credit is accounted for in the books in the period in which the underlying service received is accounted and where there is reasonable certainty in availing/utilizing the credits.

2.13 The Balances of Sundry Debtors, Sundry Creditors and Loans and Advances are subject to confirmation and consequential adjustments , if any required.

2.14 In the opinion of the management, the Current Assets, Loans and Advances have a value on realization in the ordinary course of business,equal to or at least to the aggregate amount shown in the Balance Sheet

2.15 Recognition of Grants:

The expenses in respect of Code activities are subject to Sanction/Confirmation of the Government of India and Grant- in- aid received from the Ministry of Commerce is subject to the adjustments on account of Government Audit objections, if any, partial/ non fulfillment of conditions laid down for eligibility of such Grant-in-aid, clarification by M/s Pharmaceuticals and the final decision of the Ministry in respect of the same shall be followed.

3 NOTES FORMING PART OF THE BALANCE SHEET AND PROFIT &LOSS ACCOUNT

3.1 Related parties Disclosures: Disclosures as required by Accounting Standard (AS) -18 " Related Party Disclosures" notified under the Companies (Accounting Standard) Rules , 2006 is given below.

Name of the related parties, their relationships with council and with whom transactions entered during the year :

I. Entities in which the member of the Committee of Administration is interested and nature of interest.

Committee Member	Entity in which Committee Member is interested	Nature of interest
Mr. Ashutosh Gupta	Medicamen Biotech Ltd.	Executive Director
Mr. Madan Mohan Reddy	Aurobindo Pharma Ltd	Director
Mr.Paresh Chawla	Alpa Laboratories Ltd	Director
Mr. Devang B Shah	Aadivighnesh Chem Pvt Ltd	Director
Mr. Dipak Desai	Aurochem Laboratories (India) Pvt. Ltd.	Director
Mr. Rat Desai	Bharat Parenterals Ltd	Managing Director
Mr. Tushar A Korday	Emil Pharmaceutical Industries Pvt Ltd	Director
Mr. A R Venkatesh	Global Pharma Healthcare Pvt Ltd	Chief Executive Officer
Mr. Sahil Munjal	Ind-Swift Laboratories Ltd	President & Chief Executive Officer
Mr. C Satyanarayana	Laurus Labs Pvt Ltd.	Chief Executive Officer
Mr. Rajeev Nannapaneni	Natco Pharma Ltd	Chairman & Managing Director
Mr. Dinesh Dua	Nectar Life Sciences Ltd	CEO & Director
Mr. Atul Bhopale	Nexgen Healthcare Pvt Ltd	Executive Director
Mr. Janmejay H Patel	Petlad Mahal arogya Mandal Pharmacy	Chief Executive Officer
Mr. Fazal Abbas Virji	Shalina Laboratories Pvt ltd	Director
Mr. Vijay Shah	Stallion Laboratories Pvt ltd	Managing Director

ii. **Details of Key Managerial Personnel:**
Dr. P.V. Appaji - Director General

iii. **Remuneration to Directors:**
During the Current Financial Year 2015-16 , Remuneration to Director Dr. P.V. Appaji amounting to ₹ 250851 /-

iv. The following are the disclosure in respect of Material Related Party Transactions during the year :

Company Name	Membership Fee in Rs.	Amount received for Exhibitions/BSMs	MAI Processing Charges in Rs.
Medicamen Biotech Ltd.	22686	752500	
Aurobindo Pharma Ltd	108893	436400	446439
Alpa Laboratories Ltd	11450	780148	
Aadivighnesh Chem Pvt Ltd	13740		
Aurochem Laboratories (India) Pvt. Ltd.	11450	1088410	
Bharat Parenterals Ltd	25190	910710	44186
Emil Pharmaceutical Industries Pvt Ltd	23850	182250	
Global Pharma Healthcare Pvt Ltd	22686	990234	
Ind-Swift Laboratories Ltd	100320		305345
Laurus Labs Pvt Ltd.	78070	27360	330183
Natco Pharma Ltd	81670	14820	69750
Nectar Life Sciences Ltd	37098	832127	
Nexgen Healthcare Pvt Ltd	13740		
Petlad Mahal arogya Mandal Pharmacy	22686		
Shalina Laboratories Pvt ltd	82260		
Stallion Laboratories Pvt ltd	49909	305405	
Total	**705698**	**6320364**	**1195903**

3.2 Details Regarding Advances during the year :

Unutilized MDA Advance at the beginning of the Year is Nil (Previous year Rs.13,00,507) and during the year under review, the amount of Advance received from Ministry of Commerce under this head stood at Rs. 6,00,00,000 (previous year Rs.3,65,00,000). During the Current Year an amount of Rs.4,15,00,000 has been utilized (previous year Rs.3,65,00,000) and a balance of Rs. 1,85,00,000 is unutilized (previous year is Nil).

3.3 Pursuant to the approval by the Ministry of Commerce for Grant of Marketing Development Assistance (MDA) to Individual exporters under certain eligible scheme, M/s Pharmexcil has received during the year an amount of Rs. 3,00,00,000 (previous year Rs. 2,60,00,000) and the amount Reimbursed to members stood at Rs. 2,10,63,260 (previous year Rs. 2,67,13,000).

3.4 During the year under review, an amount of Rs.14,89,35,952 (previous year Rs.2,33,25,566) was received for reimbursement of Product Registration Charges under MAI Scheme, and the amount disbursed during the year was Rs.14,87,59,331 (previous year Rs.2,50,25,162).

3.5 Unutilized MAI advance of the beginning of the year stood at Rs.3,37,46,577 (previous year Rs.2,43,65,124) and during the year under review, the amount of advance received from Ministry of Commerce under this head stood at Rs. 6,19,38,969 (previous year Rs.10,16,00,000). As against this the amount utilized by the Council was Rs.10,67,90,076 (previous year Rs.12,43,50,286).

3.6 DUES OF MICRO AND SMALL ENTERPRISES:

The information as required to be disclosed under Schedule III of the Act, w.r.t. Micro and Small Enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (Act) is as given below and the information mentioned to Trade Payables w.r.t. dues of Micro and Small Enterprises, has been determined to the extent such parties have been identified on the basis of information available with the Company and relied on by the auditors:

Particulars	2015-16	2014-15
a. Principal amount remaining unpaid as on 31st March	NIL	NIL
b. Interest due thereon as on 31st March	NIL	NIL
c. Interest paid by the Company in terms of Section 16 of Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of payment made to the supplier beyond the appointed day during the year	NIL	NIL
d. Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year but without adding the interest specified under the Act)	NIL	NIL
e Interest accrued and remaining unpaid as at 31st March	NIL	NIL
f. Further interest remainingdue and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the Act.	NIL	NIL

3.7 Membership Fees was accounted on Receipt basis and accordingly, no Provision for Membership has been made for the year end.

3.8 Provisions

Taxes on Income:

Pharmexcil has been registered under Section 12AA of Income Tax Act,1961 which is not required to pay tax subject to fulfillment of necessary conditions laid there on.

3.9 Provision for Auditors Remuneration :

Particulars	Audit Fee for the year (₹)	Service Tax there on (₹)	Total Amount (₹)
Statutory Auditors	100000	15000	115000/-
Internal Auditors	180000	27000	207000/-

4.0 Provision For Gratuity:

During the current financial year 2015-16, the Company has not provided for Gratuity.

Particulars	2015-16	2014-15
Provision for Gratuity	NIL	₹ 2643867

Payment Of Gratuity :

The Company has paid an of Amount Rs.317000/- towards Gratuity during the current financial year 2015-16.

4.1 Additional Information as required under Part-II of Schedule III of the Companies Act, 2013.

The following is the expenditure in the Foreign Currency during the financial year 2015-16:

Particulars	Amount (₹)	Amount (₹)
Expenditure in Foreign Currency	US($) 1258063	82432713
	Euro 677516	49436815

4.2 Figures have been rounded off to the nearest rupee and previous figures are regrouped / reclassified wherever necessary to confirm to the current year classification.

List of Circulars for the Year 2015-16

S.No.	Date	Subject
1	02/04/2015	Advertisement in Show Catalogue - Korea Pharma 2015
2	04/04/2015	India Pavilion at CPhI Istanbul, Turkey from 3-5th June 2015
3	06/04/2015	India Pavilion at CPhI China - 24-26th June 2015
4	06/04/2015	Request to submit data for the purpose of the exercise for All Industry Rate (AIR) of Duty Drawback for the year 2015
5	12/04/2015	Presentations/Panel Discussions on Foreign Trade Policy 2015-20
6	20/04/2015	Seminar on Export Opportunities & Challenges for Pharma SMEs - 25.04.2015
7	22/04/2015	A 9 Days Management Programme on Achieving competitive advantage in Pharmaceutiacls in Sub-Saharan Africa Market
8	24/04/2015	USP - India training Programme "Certified Pharmaceutical Good Manufacturing Practices" 18-23rd May 2015
9	24/04/2015	Hon'ble PM's Visit to Mongolia during May 2015 - Opportunity for supply of Pharmaceuticals to Mongolia
10	27/04/2015	APPEAL Request for generous Donation of Medicines to Victims of Earthquake in Nepal
11	28/04/2015	Invitation by China Medical City for Networking Dinner Meet at Delhi and Hyderabad
12	28/04/2015	FTP 2015-20 Review: Presentations made during DGFT Meeting at Hyderabad
13	29/04/2015	Payment of Challans in different Cities for DCGI office applications
14	30/04/2015	CPhI INDIA 2015
15	01/05/2015	Interactive Meet on Foreign Trade Policy 2015-20 - Its impact on Pharma Sector - 7th May 2015 at Mumbai
16	04/05/2015	Interactive Meet with Merchant Exporters on 11th May 2015 at 10:30 am at Mumbai
17	08/05/2015	Revised Timings - Interactive Meet with Merchant Exporters on 11th May 2015 at 4:00 PM at IDMA, Mumbai
18	12/05/2015	IPHEX-2015, 13-15th May 2015, Bombay Exhibition Centre, Goregaon, Mumbai

19	14/05/2015	Interactive Meeting with Delegation from Sri Lanka on 15th May 2015 (during iPHEX)
20	21/05/2015	Dubious Mail in the name of PHARMEXCIL
21	22/05/2015	CPhI Worldwide, 13-15th October 2015, IFEMA, Feria De Madrid, Spain
22	22/05/2015	Visit of "Members of Parliamentary Standing Committee on Commerce" on 26th May 2015 at Hyderabad
23	24/05/2015	Procedure for Implementation of Track & Trace System for export of Drug Formulations - DGFT Public Notice dt: 22nd May 2015
24	29/05/2015	Promote your products in China - Advertisement in Show Catalogue - CPhI China 2015
25	29/05/2015	Export Promotion Events Calender for 2015-16
26	01/06/2015	BLOCK Your Diary: Seminar on Export Opportunities and Regulatory Challenges in ASEAN Region
27	01/06/2015	1st time India Pavilion at Maghreb Pharma Expo, Algiers, Algeria from 29th September to 1st October 2015
28	02/06/2015	Expert Group on Technology for Implementation of the Trace and Track system for Export of Drug Formulations
29	08/06/2015	Workshop on - Managing Risks & Liabilities in the Pharmaceutical and Food & Beverage Sectors
30	09/06/2015	Meeting scheduled at the O/o. Dy. CDSCO, West Zone, Mumbai at 11-30 a.m. on 10th June 2015 at Mumbai
31	12/06/2015	PharmaLytica 2-3rd September 2015, Hitex, Hyderabad
32	17/06/2015	Pharmexcil Awards for Outstanding Export Performance for the years 2014-15 - Invitation for Applications
33	17/06/2015	Seminar on Export Opportunities in Pharmaceuticals
34	19/06/2015	Seminar on Bar Coding / Drug Authentication and Verification Application on 26th June (Friday) 2015
35	20/06/2015	Indo-Global Pharma Expo & Summit 2015
36	29/06/2015	EXPO-CUM-BSM in Peru followed by Business Delegation to Paraguay, Chile and Argentina (24th August - 5th September 2015)
37	30/06/2015	International Buyer Seller Meet & Seminar on 3rd and 4th July 2015 during Pharmac South at Chennai

38	01/07/2015	Free Entry for BSM (Registration required) & Seminar on Export Opportunities during 3rd -4th july 2015 at Pharmac South 2015
39	02/07/2015	Awards for companies who secured patents during April 2014 to March 2015
40	08/07/2015	Participate in Supply Side West 2015
41	09/07/2015	Reminder - Indo-Global Pharma Expo & Summit 2015 - Organised by Indus Foundation and Supported by Pharmexcil (30% Discount)
42	10/07/2015	Invitation for participation of Indian Companies in Joint Venture with M/s. Akniet Pharmaceuticals, Kazakhstan
43	10/07/2015	Promote your products in Pharmexcil's Publication titled "List of Indian Exporters (Pharmexcil Members) and Companies with International Accreditation"
44	14/07/2015	Interactive Meeting with Director & Consul (Investment) Board of Investment, Government of Thailand on 17th July 2015 at Hotel Aditya Park, Ameerpet, Hyderabad
45	16/07/2015	Revised MAI Scheme - Additional financial components for Pharma Industry
46	17/07/2015	Pharmexcil Branch office at Chennai - Opened on 3rd July 2015 - Reg.
47	18/07/2015	Information on Regulatory Procedures for Ayush products (5 Countries)
48	18/07/2015	Curtain Raiser IPHEX-LATAM: Expo-Cum-BSM (24-25th August 2015) in Peru - Additional optional provided to participate in Peru
49	20/07/2015	Save the Dates -11th Annual Meet of Pharmexcil - 22-24th September 2015
50	21/07/2015	Online Submission of MDA/MAI Claims
51	22/07/2015	Elections to the Committee of Administration - Enroll as Eligible Voter/Contestant
52	24/07/2015	Inauguration of Pharmexcil's Branch Office at Bangalore & Technical Seminar on "Export Opportunities and Regulatory Challenges for Pharmaceuticals & Traditional Medicines" on 5th August 2015
53	27/07/2015	Information regarding closure of advance licenses with DGFT and fixation of SIONs for some drugs by DGFT - information requested

54	29/07/2015	Workshops on critical Patenting Issues on Pharma and Biosimilars
55	30/07/2015	Joint Workshop by Pharmexcil & IDMA on "Pharma Product positioning and export benefits under various Government Schemes" at Chennai on 6th August 2015
56	31/07/2015	Global Pharma Business Meet
57	01/08/2015	Joint programme with WHO, UNICEF and UNFPA - 23-25 November 2015 at Denmark
58	02/08/2015	Participation in Healthcare and Medical Devices Exhibition in Kabul, Afghanistan (Stall Rentals complimentary)
59	11/08/2015	Workshop organised by GS1 India to comply with DGFT's Track and Trace Requirements
60	12/08/2015	11th Annual General Meet
61	12/08/2015	Attention: Packaging Department - Seminar on Bar Coding
62	13/08/2015	Special Measures by Department of Commerce for Promotion of Veterinary medicines and investment in Veterinary Vaccine Plants in Vietnam
63	13/08/2015	IDMA's Seminar on New insights in Tablet Manufacturing & Testing on 17th August 2015
64	13/08/2015	Pre Budget Proposals for 2016-17
65	14/08/2015	Inviting Suggestions/inputs on Draft Notification by National Biodiversity Authority (NBA) to Increase number of Commodity in the list of normally traded commodities (NTCs)
66	14/08/2015	Exporters to Russia & CIS
67	14/08/2015	First Inter-regional forum on Small and Medium Enterprises of the BRICS and SCO Members
68	19/08/2015	DCGI issues order: Fast track clearance of Export Shipments by ADCs at various ports-Reg
69	21/08/2015	Elections to 8 (eight) seats of Committee of Administration for 2015-17 - Nominations invited
70	25/08/2015	Information on Regulatory Procedures for Ayush products (5 Countries)
71	25/08/2015	DCGI delegates powers to issue NoCs to DDC / ADC, Bangalore
72	28/08/2015	India Pavilion at Arab Health 25th - 28th January 2016 at Dubai, UAE

73	28/08/2015	India Sourcing Fair in Almaty, Kazakhstan - Organised by India Trade Promotion Organisation (ITPO)
74	02/09/2015	11th Annual General Meeting - Notice
75	03/09/2015	Unique Opportunity - Meet over 70 Pharmaceutical Buyers / Importers from 25 Countries
76	04/09/2015	Attention: API Manufacturers - Expert /Top officials from PIC/S, USFDA participating API - ICH Q7 Training Course at Hyderabad (14-15 September, 2015) and Ahmedabad (17-18 September, 2015)
77	07/09/2015	Operationalization of "Oil for Export Mechanism" between India and Venezuela-Reg.
78	09/09/2015	Global Pharma Business Meet, Hyderabad: Unique Opportunity (Registration fee is reduced)
79	10/09/2015	Participate in "India Investrade" (Healthcare and Medical Devices Exhibition) from 28-30th September 2015 at Kabul, Afghanistan
80	11/09/2015	OPPORTUNITY FOR ENTERING JAPANESE PHARMA MARKET/ Business partnership
81	30/09/2015	Bar coding Public Notice by DGFT dt: 22nd May 2015-Data uploading on Central Server - compliance -regarding
82	30/09/2015	Attention: Quality Control Department : Workshop on awareness programme on Indian Pharmacopeia on 7th October, 2015 at Mumbai
83	30/09/2015	Seminar on "Export of AYUSH & Nutraceutical Products and its Procedures" on 7th October 2015 at The Fern Hotel, Ahmedabad, Gujarat-Registration Free
84	12/10/2015	Joint Venture in Kenya
85	21/10/2015	Avail the opportunity of advertising in Show Catalogue of CPhI India 2015
86	23/10/2015	Participation in Healthcare and Medical Devices Exhibition in Kabul, Afghanistan (Stall- complimentary)
87	28/10/2015	An Update on Barcoding
88	05/11/2015	Joint Venture in Jordan
89	13/11/2015	WAREHOUSING FACILITY AT NIGERIA

90	21/11/2015	India Pharma Awards: Nominations called by Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India
91	23/11/2015	Pharmexcil publication titled "List of Pharmexcil Members (Indian Pharma Exporters) and Companies with International Accreditation" - Soft Copy - Reg.
92	24/11/2015	Catalogue Show During Vietnam Medi-Pharm Expo 2015 - 2-4th December, 2015
93	08/12/2015	International Business Meet for Herbal & Ayurveda Products - 12 & 13th December 2015 at BHU, Varanasi
94	10/12/2015	INTERNATIONAL BUSINESS MEET FOR HERBAL & AYURVEDA PRODUCTS Dates: 12 & 13th Dec.2015 at BHU, Varanasi
95	11/12/2015	IPHEX AFRICA, Nigeria & BSM in Sudan - 17-23rd February 2016
96	12/12/2015	EXPO-CUM-BSM in Russia followed by Business Delegation to Belarus and Uzbekistan (24-February - 6th March 2016)
97	17/12/2015	iPHEX-2016, 27-29th April 2016 at Mumbai
98	17/12/2015	ATTENTION Participants at IPC - Regulators meet at Indian Pharmaceutical Congress (IPC) at Mysuru
99	19/12/2015	International Business Meet (RBSM) for Pharmaceuticals & Ayush Products (In the side lines of India Pharma Expo) -7-8th January 2016 at BIEC, Bengaluru
100	01/01/2016	International Business meet for Pharmaceuticals & Natural Products, 7 & 8 Jan 2016 at BIEC, Bengaluru
101	04/01/2016	Recommendations for Overseas Business Visitors for IPHEX-2016
102	05/01/2016	Information on International Payment Defaulting Companies
103	08/01/2016	Promote your Products in GCC countries - Advertise in Show Catalogue of Arab Health 2016
104	13/01/2016	Notice from CDSCO: Relaxation on the requirement of "No Objection Certificate" for export consignments to USA, Canada, Japan, Australia and EU
105	14/01/2016	Barcoding-DGFT issues Notification - SSI Manufacturers exempted up to 31.03.2017
106	18/01/2016	Participation in CPhI Worldwide, 4-6th October 2016, Fira de Barcelona Gran Via, Barcelona, Spain

107	22/01/2016	Sponsorship Opportunities - IPHEX Africa in Nigeria & BSM in Sudan
108	22/01/2016	BSM/Pharma Business Delegation to Myanmar, Singapore, Thailand
109	26/01/2016	BioAsia2016 - Pharmexcils technical Seminars & Ineractive Sessions with Overseas Buyers/govt/UN procurement Agencies and Regulators
110	28/01/2016	Grab this Unique learning opportunity - Two Days Certification Course on "Export Import Management"
111	28/01/2016	India Pavilion at Korea Pharm - South Korea 26-29 April 2016
112	29/01/2016	Seminar on Outreach Programme for Utilization of FTAs & Other Pharma related issues
113	29/01/2016	Seminar under "Niryat Bandhu" in Mumbai for Pharma Cluster
114	30/01/2016	WAREHOUSING FACILITY AT NIGERIA
115	05/02/2016	BioAsia - Hyderabad 8-9th February 2016, HICC, Hyderabad
116	05/02/2016	Various Panels in Committee of Administration
117	08/02/2016	Notification issued by MoH inviting public comments: G.S.R.1011 (E) dated 29.12.2015 regarding amendment in Drugs & Cosmetics Act
118	09/02/2016	INAUGURATION OF 13TH BIOASIA
119	10/02/2016	REVISED - BSM / Pharma Business Delegation to Cambodia (14th to 16th March 2016), Vietnam (17th to 19th March 2016) & Thailand (20th to 23rd March 2016
120	11/02/2016	India Pavilion (4th Edition) at PHARMACONEX, Cairo, Egypt - 19-21st April 2016
121	11/02/2016	Participation in CPhI-Tokyo, 20-22nd April, 2016
122	12/02/2016	Good news - DGFT Trade Notice no. 16/2016 dated 10.02.2016
123	13/02/2016	Seminar under "Niryat Bandhu" in Mumbai for Pharma Cluster on Thursday, 11th February 2016 at Sci-tech Centre, Mumbai is postponed to 17th February 2016.
124	13/02/2016	PHARMEXCIL DIGEST 2016: Issue 1, February 2016
125	15/02/2016	Interactive Meeting with Commerce Secretary, Smt. Rita Teaotia, IAS, Secretary on 17th Feb.2016 at ISB, Hyderabad-request for submission of issues/suggestions and active participation.

126	19/02/2016	Interactive Seminar with UKMHRA Officials on 26th Feb.2016 at Taj Deccan, Hyderabad
127	19/02/2016	USP-Dietary Supplements workshop in collaboration with Pharmexcil on Thursday, 25-Feb-2016 at Hotel Courtyard by Marriot, Mumbai
128	24/02/2016	Post Budget Analysis 2016-17 (focussed to Pharma Sector) by PricewaterhouseCoopers (PwC) Presentation on 01 Mar 2015-Hyderabad
129	01/03/2016	Interactive Meeting with Smt. Rita Teaotia, IAS, Secretary, Department of Commerce - 4th March 2016, Hyderabad
130	04/03/2016	Distribution of Catalogues - Austropharm - Vienna, Austria
131	09/03/2016	Renewal of RCMC for 2016-17
132	09/03/2016	Two Days Certification Course on Export Import Management conducted by Pharmexcil - 6-7th April 2016 in Baddi, Himachal Pradesh
133	15/03/2016	Export of Pharmaceuticals & Medical Equipment to Sudan not Subject to US Sanctions
134	18/03/2016	1st Time Pavilion at Iran Health, Tehran, Iran
135	21/03/2016	PHARMEXCIL DIGEST 2016: Issue 2, March 2016
136	28/03/2016	Serbian State-Owned Galenika pharmaceuticals is looking for Strategic Partner
137	28/03/2016	Avail Special Offer: First Time Exhibitors- IPHEX-2016, 27-29 April 2016, Bombay Exhibition Centre, Mumbai
138	30/03/2016	Jafza Investor Meet
139	31/03/2016	India Pavilion at Vita Foods 2016 at Geneva, Switzerland from 10-12th May 2016
140	31/03/2016	Two days Certification course on "Export Import Management" conducted by PHARMEXCIL on 04th & 05th May 2016 in Indore, Madhya Pradesh

List of Trade Enquiries for the year 2015-16

S.No.	Date	Subject
1	6-May-15	Trade Enquiry - Srbija
2	11-May-15	Trade Enquiry - Chile
3	28-May-15	Tender Enquiry - Bangladesh
4	16-Jun-15	Trade Enquiry - Myanmar
5	18-Jun-15	Trade Enquiry - Sri Lanka
6	23-Jun-15	Trade Enquiry - Sri Lanka
7	24-Jun-15	Trade Enquiry - Peru
8	29-Jun-15	Attn: Manufacturers of Pharmaceuticals - Trade Enquiry - Jordan
9	30-Jun-15	Trade Enquiry - Chile
10	15-Jul-15	Tender Enquiry - Ivory Coast
11	6-Aug-15	Trade Enquiry - Uzbekistan
12	14-Aug-15	Trade Enquiry - Sri Lanka
13	15-Sep-15	Trade Enquiry - Sri Lanka
14	17-Nov-15	Trade Enquiry - West Indies
15	11-Mar-16	Trade Enquiry - RITES Limited
16	17-Mar-16	Trade Enquiry - KOREA

Beneficiaries under MAI Scheme 2015-16

Sl No	BENEFICIARY	Ministry Sanction Letter No. Date	Disbursement Amount in 'Rs'
1	BKRS Pharma Private Limited	15/44/2014-EP(Engg) dt:12.05.15	1744661
2	Karan Healthcare Private Limited	15/44/2014-EP(Engg) dt:12.05.15	939088
3	Neuland Laboratories Limited	15/44/2014-EP(Engg) dt:12.05.15	1783064
4	CTX Life Sciences Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	3362272
5	SMS Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	4820085
6	Sri Krishna Pharmaceuticals Ltd	15/44/2014-EP(Engg) dt:12.05.15	1905769
7	Troikaa Pharmaceuticals Ltd	15/44/2014-EP(Engg) dt:12.05.15	780261
8	Laurus Labs Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	2686210
10	Sentiss Pharma Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	556751
11	Mylan Laboratories Limited	15/44/2014-EP(Engg) dt:12.05.15	3187306
12	MSN Laboratories Private Limited	15/44/2014-EP(Engg) dt:12.05.15	3389561
13	MSN Pharmachem Private Limited	15/44/2014-EP(Engg) dt:12.05.15	3022693
14	MSN Organics Private Limited	15/44/2014-EP(Engg) dt:12.05.15	98025
15	J.B.Chemicals & Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	566437
16	Synthokem Labs Pvt Limited	15/44/2014-EP(Engg) dt:12.05.15	1342179
17	Dr.Reddy'S Laboratories Ltd	15/44/2014-EP(Engg) dt:12.05.15	7727687
18	Agog Pharma Ltd	15/44/2014-EP(Engg) dt:12.05.15	1055391
19	Macleods Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	5241007
20	Kusum Healthcare Private Limited	15/44/2014-EP(Engg) dt:12.05.15	2637054
21	Flaminigo Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	1518165
22	Emcure Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	1760337
23	Glenmark Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	374979
24	Ajanta Pharma Limited	15/44/2014-EP(Engg) dt:12.05.15	1710240
25	Indian Herbs Specialities Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	111348
26	Yash Pharma Laboratories Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	62118
27	Vasudha Pharma Chem Limited	15/44/2014-EP(Engg) dt:12.05.15	101118
28	S.G.Pharma Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	396462
29	Umedica Laboratories Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	746659

30	Nirma Ltd	15/44/2014-EP(Engg) dt:12.05.15	79270
31	Zifam Pinnacle Healthcare Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	56624
32	Anuh Pharma Ltd	15/44/2014-EP(Engg) dt:12.05.15	35425
33	Mankind Pharma Limited	15/44/2014-EP(Engg) dt:12.05.15	161815
34	Anuh Pharma Ltd	15/44/2014-EP(Engg) dt:12.05.15	35425
35	Orchid Chemicals & Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	325703
36	Polchem Hygiene Laboratories Pvt Ltd		73590
37	Arvind Remedies Ltd	15/44/2014-EP(Engg) dt:12.05.15	217157
38	Ind Swift Laboratories Ltd	15/44/2014-EP(Engg) dt:12.05.15	334780
39	Ind Swift Limited	15/44/2014-EP(Engg) dt:12.05.15	1208741
40	Aarti Drugs Ltd	15/44/2014-EP(Engg) dt:12.05.15	580235
41	Oxford Laboratories Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	364608
42	Sirmaxo Chemicals Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	30908
43	Agio Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	2147592
44	Aurobindo Pharma Limited	15/44/2014-EP(Engg) dt:12.05.15	1664702
45	Naprod Life Sciences Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	380770
46	Mankind Pharma Limited	15/44/2014-EP(Engg) dt:12.05.15	27125
47	Sequent Scientific Limited	15/44/2014-EP(Engg) dt:12.05.15	580235
48	Megant Pharma Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	110590
49	Gland Chemicals Pvt.Ltd	11/34/2015-E&MDA dt:29.12.2015	2126400
50	Zest Pharma	11/34/2015-E&MDA dt:29.12.2015	153137
51	Zest Pharma	11/34/2015-E&MDA dt:29.12.2015	267541
52	Zest Pharma	11/34/2015-E&MDA dt:29.12.2015	557328
53	Fredun Pharmaceuticals Ltd	11/34/2015-E&MDA dt:29.12.2015	233089
54	Glochem Industries Limited	11/34/2015-E&MDA dt:29.12.2015	2830240
55	Virupaksha Organics Limited	11/34/2015-E&MDA dt:29.12.2015	925710
56	Nosch Labs Private Limited	11/34/2015-E&MDA dt:29.12.2015	128549
57	Universal Pharmaceuticals Ltd	11/34/2015-E&MDA dt:29.12.2015	112446
58	Universal Pharmaceuticals Ltd	11/34/2015-E&MDA dt:29.12.2015	102382
59	Virchow Healthcare Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	55940
60	Vexta Laboratories Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	540526

61	Til Healthcare Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	55458
62	Gepach International	11/34/2015-E&MDA dt:29.12.2015	52339
63	Unique Pharmaceutical Laboratories	11/34/2015-E&MDA dt:29.12.2015	479234
64	J.B.Chemicals & Pharmaceuticals Limited	11/34/2015-E&MDA dt:29.12.2015	523327
65	Bharat Parenterals Limited	11/34/2015-E&MDA dt:29.12.2015	687501
66	Symed Labs Limited	11/34/2015-E&MDA dt:29.12.2015	587384
67	Symed Labs Limited	11/34/2015-E&MDA dt:29.12.2015	3526935
68	Emcure Pharmaceuticals Limited	11/34/2015-E&MDA dt:29.12.2015	5000000
69	Emcure Pharmaceuticals Limited	11/34/2015-E&MDA dt:29.12.2015	5000000
70	Shrey Nutraceuticals & Herbals Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	1003054
71	Biomedicare (India) Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	601181
72	Karan Healthcare (P) Ltd	11/34/2015-E&MDA dt:29.12.2015	1328209
73	Ctx Life Sciences Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	1319026
74	Ctx Life Sciences Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	1231744
75	Neuland Laboratoreis Limited	11/34/2015-E&MDA dt:29.12.2015	943800
76	Neuland Laboratoreis Limited	11/34/2015-E&MDA dt:29.12.2015	1895697
77	Neuland Laboratoreis Limited	11/34/2015-E&MDA dt:29.12.2015	2328004
78	Kusum Healthcare Pvt Ltd	11/34/2015-E&MDA dt:29.12.2015	537538
79	Bonita Pharmaceuticals Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	160498
80	Sava Medica Limited	11/34/2015-E&MDA dt:29.12.2015	387864
81	Fourrts (India) Laboratories Pvt Ltd	11/34/2015-E&MDA dt:29.12.2015	835095
82	Fourrta (India) Laboratoreis Pvt Ltd	11/34/2015-E&MDA dt:29.12.2015	168768
83	Bkrs Pharma Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	961565
84	Bkrs Pharma Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	137338
85	Rhydburg Pharmaceuticals Ltd	11/34/2015-E&MDA dt:29.12.2015	458888
86	Centaur Pharmaceuticals Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	1068698
87	Centaur Pharmaceuticals Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	3234097
88	Sirmaxo Chemicals Pvt Ltd	11/34/2015-E&MDA dt:29.12.2015	67962
89	Macleods Pharmaceuticals Limited	11/34/2015-E&MDA dt:29.12.2015	479103
90	Macleods Pharmaceuticals Limited	11/34/2015-E&MDA dt:29.12.2015	3798276
91	Agog Pharma Limited	11/34/2015-E&MDA dt:29.12.2015	1976606

92	Agog Pharma Limited	11/34/2015-E&MDA dt:29.12.2015	2128513
93	Alice Pharma Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	134339
94	Ind-Swift Laboratories Ltd	11/34/2015-E&MDA dt:29.12.2015	4070764
95	Ind-Swift Limited	11/34/2015-E&MDA dt:29.12.2015	287546
96	Aristo Pharmaceuticals Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	634122
97	Mylan Laboratories Limited	11/34/2015-E&MDA dt:29.12.2015	1829883
98	Vasudha Pharma Chem Limited	11/34/2015-E&MDA dt:29.12.2015	117343
99	Glenmark Pharmaceuticals Ltd	11/34/2015-E&MDA dt:29.12.2015	5000000
100	Orchid Chemicals & Pharmaceuticals Ltd	11/34/2015-E&MDA dt:29.12.2015	268925
101	Mankind Pharma Limited	11/34/2015-E&MDA dt:29.12.2015	656909
102	Mankind Pharma Limited	11/34/2015-E&MDA dt:29.12.2015	382443
103	Aurobindo Pharma Limited	11/34/2015-E&MDA dt:29.12.2015	1876746
104	Aurobindo Pharma Limited	11/34/2015-E&MDA dt:29.12.2015	4597062
105	Umedica Laboratories Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	404387
106	Aarti Drugs Limited	11/34/2015-E&MDA dt:29.12.2015	1160846
107	Aarti Drugs Limited	11/34/2015-E&MDA dt:29.12.2015	929022
108	Msn Laboratories Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	228640
109	Msn Laboratories Pvt. Ltd	11/34/2015-E&MDA dt:29.12.2015	285788
110	Hetero Labs Limited	15/44/2014-EP(Engg) dt:12.05.15	820230
111	Torrent Pharmaceuticals Limited	15/44/2014-EP(Engg) dt:12.05.15	5000000
112	Zest Pharma	15/44/2014-EP(Engg) dt:12.05.15	709263
113	Caplin Point Laboratoreis Limited	15/44/2014-EP(Engg) dt:12.05.15	251962
114	Symed Labs Limited	15/44/2014-EP(Engg) dt:12.05.15	581302
115	Glochem Industries Limited	15/44/2014-EP(Engg) dt:12.05.15	195613
116	Rhydburg Pharmaceuticals Ltd	15/44/2014-EP(Engg) dt:12.05.15	84922
117	Alice Pharma Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	167693
118	Astra Lifecare (India) Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	143884
119	Harasha Pharma Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	322455
120	Protech Biosystems Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	622519
121	Fourrts (India) Laboratories Pvt Ltd	15/44/2014-EP(Engg) dt:12.05.15	692484
122	Bharat Parenterals Limited	15/44/2014-EP(Engg) dt:12.05.15	161500

123	Apoorv International	15/44/2014-EP(Engg) dt:12.05.15	132073
124	Fredun Pharmaceuticals Ltd	15/44/2014-EP(Engg) dt:12.05.15	131649
125	Aristo Pharmaceuticals Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	358897
126	Nakoda Chemicals Ltd	15/44/2014-EP(Engg) dt:12.05.15	574580
127	Asmoh Laboratoreis Ltd	15/44/2014-EP(Engg) dt:12.05.15	81429
128	Gepach International	15/44/2014-EP(Engg) dt:12.05.15	10469
129	Virchow Healthcare Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	271663
130	Rhydburg Pharmaceuticals Ltd	15/44/2014-EP(Engg) dt:12.05.15	160758
131	Q-Rexa Pharmaceuticals Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	211113
132	Pharmaserv Solutions Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	573251
133	Bhargava Phytolabs Ltd	15/44/2014-EP(Engg) dt:12.05.15	277032
134	Shrey Nutraceuticals & Herbals Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	52185
135	Verve Human Care Laboratories	15/44/2014-EP(Engg) dt:12.05.15	14222
136	Theon Pharmaceuticals Ltd	15/44/2014-EP(Engg) dt:12.05.15	65120
137	Infugen Pharma Pvt. Ltd	15/44/2014-EP(Engg) dt:12.05.15	111246
138	Envoate Biolife	15/44/2014-EP(Engg) dt:12.05.15	75840
			148759331

Beneficiaries under MDA Scheme 2015-16

Sl No	Name of the Company	Name of the Event	Amount
1	Chiros Pharma	BSM Asean 2014	55645
2	Shabbir Medical Hall	BSM Asean 2014	63000
3	Akhil Healthcare Pvt Ltd	Pharmaconex 2015	136939
4	Century Pharmaceuticals Ltd	Pharmaconex 2015	200000
5	Delta Finochem Pvt. Ltd	Pharmaconex 2015	200000
6	Everest Organics Ltd	Pharmaconex 2015	200000
7	Index	Pharmaconex 2015	200000
8	India Phosphate	Pharmaconex 2015	181950
9	Macsen Laboratories	Pharmaconex 2015	152667
10	Natural Capsules Ltd	Pharmaconex 2015	198337
11	Novo Excipients Pvt. Ltd.	Pharmaconex 2015	200000
12	Patel Chem Specialities Pvt Ltd	Pharmaconex 2015	191743
13	Pelltech Healthcare Pvt Ltd	Pharmaconex 2015	124254
14	Pharmachine India	Pharmaconex 2015	185380
15	Rasino Herbs Pvt Ltd	Pharmaconex 2015	135700
16	Shashi Phytochemical Industries	Pharmaconex 2015	200000
17	Shreeji Pharma International	Pharmaconex 2015	200000
18	Sunil Healthcare Ltd	Pharmaconex 2015	200000
19	Supreem Pharma Mysore Pvt Ltd	Pharmaconex 2015	200000
20	Terrace Pharmaceuticals Pvt Ltd	Pharmaconex 2015	135700
21	Verve Humancare Laboratories	Pharmaconex 2015	106903
22	Dr. Sabharwal's Manufacturing Labs Ltd	CPhI Japan 2015	150000
23	Metina Pharm Consulting Pvt Ltd	CPhI Japan 2015	150000
24	Shodhana Laboratories Ltd	CPhI Japan 2015	150000
25	Gland Chemicals Ltd	Korea Pharm 2015	150000
26	Orbit Lifescience Pvt. Ltd.	Korea Pharm 2015	150000
27	Stabicon Life Sciences Pvt Ltd	Korea Pharm 2015	150000
28	Vikram Thermo India Ltd	Korea Pharm 2015	150000
29	Bio Pharma Laboratories Pvt Ltd	Vita Foods 2015	150000

30	Natural Capsules Ltd	Vita Foods 2015	150000
31	Sunil Healthcare Ltd	Vita Foods 2015	150000
32	TulsiAmrit Pvt Ltd	Vita Foods 2015	150000
33	Unique Biotech Ltd	Vita Foods 2015	150000
34	Auro Laboratories Limited	CPhI Turkey 2015	150000
35	Dns Fine Chemicals & Laboratories Pvt. Ltd.	CPhI Turkey 2015	150000
36	Govind Laboratories Pvt. Ltd.	CPhI Turkey 2015	150000
37	Grace Drugs & Pharmaceuticals	CPhI Turkey 2015	150000
38	Hexagon Nutrition Pvt. Ltd.	CPhI Turkey 2015	150000
39	Kenoor Organics Pvt. Ltd.	CPhI Turkey 2015	150000
40	LabelaRegsources Pvt. Ltd.	CPhI Turkey 2015	150000
41	Meenaxy Pharma Pvt. Ltd.	CPhI Turkey 2015	150000
42	Mehta Pharmaceutical Industries	CPhI Turkey 2015	135000
43	Micromaster Laboratories Pvt. Ltd.	CPhI Turkey 2015	150000
44	Novo Excipients Pvt. Ltd.	CPhI Turkey 2015	150000
45	RiocareIndia Pvt. Ltd	CPhI Turkey 2015	150000
46	Rumit International	CPhI Turkey 2015	150000
47	Shashi Phytochemical Industries	CPhI Turkey 2015	150000
48	Shreeji Pharma International	CPhI Turkey 2015	150000
49	ShubhamPharmachem Pvt. Ltd.	CPhI Turkey 2015	150000
50	Supreem Pharmaceuticals Mysore Pvt Ltd	CPhI Turkey 2015	150000
51	Swati Spentose Pvt. Ltd.	CPhI Turkey 2015	150000
52	Swiss ParenteralsPvt.Ltd.	CPhI Turkey 2015	150000
53	Biophore India Pharmaceuticals Ltd.,	CPhI China 2015	135000
54	Everest Organics Ltd.,	CPhI China 2015	150000
55	Macsen Laboratories	CPhI China 2015	135000
56	Magbro Health Care Pvt Ltd	CPhI China 2015	150000
57	Pell Tech Health Care Private Limited	CPhI China 2015	135000
58	Rasino Herbs Pvt. Ltd	CPhI China 2015	150000
59	Resonance Specialties Limited	CPhI China 2015	135000
60	Sainor Pharma Private Limited	CPhI China 2015	150000

61	SL Drugs And Pharmaceuticals	CPhI China 2015	150000
62	Apex Drug House	BSM LAC 2015	100000
63	Cachet Pharmaceuticals Pvt. Ltd.	BSM LAC 2015	100000
64	Century Pharmaceuticals Limited.	BSM LAC 2015	100000
65	Dr. Sabharwal's Medicals Pvt. Ltd	BSM LAC 2015	100000
66	Dr. Sabharwal's Mfg. Labs Ltd	BSM LAC 2015	100000
67	Everest Organics Ltd.	BSM LAC 2015	90000
68	Felix Pharma Labs (A Part Of Chempi Fine Group)	BSM LAC 2015	100000
69	Gufic Stridden Biopharma Pvt. Ltd.	BSM LAC 2015	100000
70	Healthcaps India Limited	BSM LAC 2015	100000
71	Hexagon Nutrition Pvt.Ltd.	BSM LAC 2015	100000
72	InnovaCaptab	BSM LAC 2015	90000
73	Labdhi Pharmaceuticals	BSM LAC 2015	100000
74	Medicamen Biotech Ltd	BSM LAC 2015	100000
75	Mediwin Pharmaceuticals	BSM LAC 2015	90000
76	Mystical Biotech Pvt Ltd.	BSM LAC 2015	100000
77	Pell Tech Health Care Pvt. Ltd	BSM LAC 2015	90000
78	Rakshit Drugs Pvt Ltd	BSM LAC 2015	90000
79	Riocare India Pvt. Ltd	BSM LAC 2015	100000
80	Sai Med Pharma Systems Pvt Ltd	BSM LAC 2015	100000
81	Sunil Healthcare Limited	BSM LAC 2015	90000
82	Supreme Pharma Healthcare Pvt Ltd.	BSM LAC 2015	90000
83	Swiss Parenterals Pvt. Ltd.	BSM LAC 2015	90000
84	Uni Medico Labs	BSM LAC 2015	100000
85	Verve Human Care Laboratories	BSM LAC 2015	100000
86	Ator Health Care Pvt Ltd (Pell Tech)	Maghreb Expo 2015	180000
87	Concept Engg Co	Maghreb Expo 2015	200000
88	Disto Pharmaceuticals Pvt Ltd	Maghreb Expo 2015	200000
89	Dr Smita's Herbal Laboratories	Maghreb Expo 2015	180042
90	Fortcaps Healthcare Ltd	Maghreb Expo 2015	200000
91	Grace Drugs & Pharmaceuticals	Maghreb Expo 2015	200000

92	HerbaNeuvaImpex Pvt Ltd	Maghreb Expo 2015	180000
93	Hexagon Nutrition Pvt Ltd	Maghreb Expo 2015	200000
94	Jpn Pharma Pvt Ltd	Maghreb Expo 2015	200000
95	LabelaRegsources Pvt Ltd	Maghreb Expo 2015	200000
96	M B Sugars & Pharmaceuticals Ltd	Maghreb Expo 2015	200000
97	Meenaxy Pharma Pvt Ltd	Maghreb Expo 2015	200000
98	Octavius Pharma Pvt Ltd	Maghreb Expo 2015	200000
99	Parth Overseas	Maghreb Expo 2015	200000
100	ShubhamPharmachem Pvt Ltd	Maghreb Expo 2015	200000
101	Spansules Formulations	Maghreb Expo 2015	200000
102	SushenMedicamentos Pvt Ltd	Maghreb Expo 2015	180000
103	Cultivator Natural Products Pvt Ltd	Supply Side West 2015	150000
104	Herbal Creations	Supply Side West 2015	150000
105	Indian Herbs Extractions	Supply Side West 2015	150000
106	Ions Pharma	Supply Side West 2015	150000
107	Neelam Phyto Extracts	Supply Side West 2015	150000
108	Perennial Life Sciences	Supply Side West 2015	150000
109	Sa Herbal Bioactive	Supply Side West 2015	150000
110	TulsiAmrit Pvt Ltd	Supply Side West 2015	150000
111	Alchemy Medicines Pvt Ltd	Iphex Africa 2015-16	70000
112	Alpa Laboratories Ltd	Iphex Africa 2015-16	70000
113	Cachet Pharmaceuticals Pvt Ltd	Iphex Africa 2015-16	70000
114	Charak Pharma Pvt Ltd	Iphex Africa 2015-16	70000
115	Chiros Pharma	Iphex Africa 2015-16	70000
116	Concept Pharmaceuticals	Iphex Africa 2015-16	70000
117	Ecobliss India Private Limited	Iphex Africa 2015-16	70000
118	Gepach International	Iphex Africa 2015-16	70000
119	Global Pharma Healthcare Pvt Ltd	Iphex Africa 2015-16	70000
120	Healthcaps India Ltd	Iphex Africa 2015-16	70000
121	Hiral Labs Ltd	Iphex Africa 2015-16	70000
122	L'amarHealthcare	Iphex Africa 2015-16	70000

123	Magbro Healthcare Private Limited	Iphex Africa 2015-16	70000
124	Medibios Laboratories Pvt. Ltd.	Iphex Africa 2015-16	70000
125	Meridian Enterprises Pvt Ltd	Iphex Africa 2015-16	70000
126	Ravenbhel Healthcare Pvt Ltd	Iphex Africa 2015-16	70000
127	Ravian Life Science Pvt. Ltd.	Iphex Africa 2015-16	70000
128	Sunrise International Labs Ltd	Iphex Africa 2015-16	70000
129	Suraksha Pharma Pvt Ltd	Iphex Africa 2015-16	70000
130	Swiss Parenterals Private Limited	Iphex Africa 2015-16	70000
131	Sydler Remedies Pvt Ltd	Iphex Africa 2015-16	70000
132	Vasu Healthcare Pvt Ltd	Iphex Africa 2015-16	70000
133	West-Coast Pharmaceutical Works Ltd	Iphex Africa 2015-16	70000
134	Akhil Healthcare Pvt Ltd	Cis 2015-16	70000
135	Concept Engg	Cis 2015-16	70000
136	Gepach International	Cis 2015-16	70000
137	Healthcaps India Ltd	CIS 2015-16	70000
138	Hexagon Nutrition Pvt.Ltd	Cis 2015-16	70000
139	Magbro Healthcare Private Limited	Cis 2015-16	70000
140	Merix Laboratories Pvt Ltd	Cis 2015-16	70000
141	Natural Capsules Ltd	Cis 2015-16	70000
142	Octavius Pharma Pvt. Ltd.	Cis 2015-16	70000
143	Perdaman Pharmaceuticals	Cis 2015-16	70000
144	Phytotech Extracts Pvt Ltd	Cis 2015-16	70000
145	Prince Care Pharma Pvt Ltd	Cis 2015-16	70000
146	Ravenbhel Biotech	Cis 2015-16	70000
147	Sai Med Pharma Systems Pvt Ltd.	Cis 2015-16	70000
148	ShubhamPharmachemPvt.Ltd	Cis 2015-16	70000
149	U.S.Steriles	Cis 2015-16	70000
150	Vee Excel Drugs & Pharmaceuticals (P) Ltd.	Cis 2015-16	70000
151	Verve Human Care Laboratories	Cis 2015-16	70000
152	Abhis Pharma Specialities	Asean 2015-16	70000
153	Alchemy Medicines Pvt Ltd	Asean 2015-16	70000

154	Bkrs Pharma Pvt Ltd	Asean 2015-16	70000
155	Chiros Pharma	Asean 2015-16	70000
156	Corona Remedies Pvt Ltd	Asean 2015-16	70000
157	Dcpl Life Science	Asean 2015-16	70000
158	Farmachem Life Pvt Ltd	Asean 2015-16	70000
159	Gepach International	Asean 2015-16	70000
160	Gpt Pharmaceuticals Pvt Ltd	Asean 2015-16	70000
161	Grace Drugs & Pharmaceuticals	Asean 2015-16	70000
162	Hexagon Nutrition Pvt Ltd	Asean 2015-16	70000
163	Hiral Labs Ltd	Asean 2015-16	70000
164	Inlife Pharma Pvt Ltd	Asean 2015-16	70000
165	Medsource Ozone Biomedicals Pvt Ltd	Asean 2015-16	70000
166	Merit Organics Ltd	Asean 2015-16	70000
167	Moraceae Pharmaceuticals Pvt Ltd	Asean 2015-16	70000
168	Pr Pharma Source Pvt Ltd	Asean 2015-16	70000
169	Ravenbhel Healthcare Pvt Ltd	Asean 2015-16	70000
170	Sain Medicaments Pvt Ltd	Asean 2015-16	70000
171	Salve Pharmaceuticals Pvt Ltd	Asean 2015-16	70000
172	SanceLabortories Pvt Ltd	Asean 2015-16	70000
173	Sanzyme Pvt Ltd	Asean 2015-16	70000
174	Subhra Pharma Pvt Ltd	Asean 2015-16	70000
175	Sydler Remedies Pvt Ltd	Asean 2015-16	70000
176	Tarush Healthcare	Asean 2015-16	70000
177	Taurian Pharma Pvt Ltd	Asean 2015-16	70000
178	Vaishali Pharma Pvt Ltd	Asean 2015-16	70000
179	Zota Healthcare Ltd	Asean 2015-16	70000
			21063260

Pharmaceuticals Export Promotion Council of India

(Setup by Ministry of Commerce & Industry, Govt. of India)

Head Quarters / Regd. Office

101, Aditya Trade Center, Ameerpet, Hyderabad – 500 038.
Ph: 91-40-23735462/66, Fax: 91-4027375464
E-mail: info@pharmexcil.com

Regional Office - Mumbai

TV Industrial Estate, Unit No. 211, 2nd Floor, 248-A S.K. Ahire Marg, Worli, Mumbai - 400 030.
Ph: 91-22-24938750/51/58/59, Fax: 91-22-24938822
E-mail: romumbai@pharmexcil.com

Regional Office - New Delhi

305, Padma Tower II, 22, Rajendra Palace, New Delhi – 110 008.
Ph: 91-11-41536654 / 45062550, Fax: 91-11-41536658
E-mail: rodelhi@pharmexcil.com

Branch Office - Ahmedabad

7-C, Trade Centre, Near Stadium Cross Road, Navarangpura, Ahmedabad – 380 009.
Ph: 91-79-40050497 E-mail: boahmedabad@pharmexcil.com

Website: www.pharmexcil.com